Gyre Therapeutics (GYRE)
A majority-owned Beijing unit sells China's pirfenidone lung-fibrosis therapy while San Diego runs the antifibrotic pipeline.
$7.33
vs last close−0.16 (−2.20%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32 | 27 | 27 | 25 | 25 | 28 | 22 | 30 | 31 | 37 | 23 | 29 |
| Cost of revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 |
| Gross profit | 31 | 26 | 26 | 24 | 25 | 27 | 21 | 29 | 29 | 35 | 21 | 27 |
| 18 | 118 | 18 | 21 | 20 | 26 | 19 | 31 | 22 | 35 | 31 | 41 | |
| Research & development | 3 | 5 | 2 | 3 | 3 | 4 | 3 | 8 | 2 | 5 | 7 | 19 |
| 15 | 27 | 16 | 18 | 18 | 22 | 16 | 22 | 20 | 31 | 21 | 22 | |
| Selling & marketing | 14 | 16 | 13 | 14 | 14 | 17 | 11 | 15 | 15 | 24 | 14 | 14 |
| General & administrative | 1 | 10 | 3 | 3 | 4 | 5 | 5 | 7 | 4 | 7 | 7 | 8 |
| Other expenses | 0 | 86 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Operating income | 13 | −92 | 8 | 3 | 4 | 1 | 2 | −2 | 7 | 0 | −9 | −14 |
| −2 | −9 | 4 | 3 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Other non-operating income | 0 | −86 | −4 | −3 | 0 | 0 | −2 | 0 | −1 | 0 | 0 | 0 |
| Income before tax | 11 | −100 | 12 | 6 | 4 | 1 | 5 | −2 | 8 | 0 | −9 | −14 |
| Income tax expense | 4 | 1 | 3 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | −1 | 0 |
| Net income from continuing operations | 8 | −101 | 10 | 5 | 3 | 1 | 4 | −2 | 6 | −1 | −9 | −14 |
| Net income | 4 | −101 | 8 | 4 | 1 | 0 | 3 | 1 | 4 | −2 | −9 | −11 |
| EPS, basic | $0.05 | −$1.39 | $0.09 | $0.04 | $0.01 | −$0.00 | $0.03 | −$0.02 | $0.04 | −$0.02 | −$0.10 | −$0.12 |
| EPS, diluted | $0.05 | −$1.39 | $0.07 | $0.03 | $0.01 | −$0.00 | $0.00 | −$0.03 | $0.03 | −$0.02 | −$0.10 | −$0.12 |
| Weighted average shares, basic | 77 | 77 | 83 | 86 | 86 | 85 | 86 | 89 | 89 | 91 | 91 | 101 |
| Weighted average shares, diluted | 77 | 77 | 103 | 104 | 103 | 102 | 102 | 89 | 103 | 103 | 91 | 101 |
| EBITDA | 13 | −5 | 13 | 6 | 4 | 1 | 5 | −1 | 8 | 1 | −9 | −14 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| EBIT | 13 | −5 | 12 | 6 | 4 | 1 | 5 | −2 | 8 | 0 | −9 | −14 |